Two-Year Toxicity and Efficacy of Carbon Ion Radiotherapy in the Treatment of Localized Prostate Cancer: A Single-Centered Study

Ping Li\textsuperscript{1,2,3}, Zhengshan Hong\textsuperscript{1,2,3}, Yongqiang Li\textsuperscript{2,3,4}, Shen Fu\textsuperscript{5,6} and Qing Zhang\textsuperscript{1,2,3}\textsuperscript{*}

\textsuperscript{1} Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai, China, \textsuperscript{2} Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai, China, \textsuperscript{3} Shanghai Key Laboratory of Radiation Oncology, Shanghai, China, \textsuperscript{4} Department of Medical Physics, Shanghai Proton and Heavy Ion Center, Shanghai, China, \textsuperscript{5} Key Laboratory of Nuclear Physics and Ion-Beam Application (MOE), Fudan University, Shanghai, China, \textsuperscript{6} Department of Radiation Oncology, Shanghai Concord Cancer Hospital, Shanghai, China

\textbf{Background:} We aimed at determining the safety and feasibility of spot-scanning carbon ion radiotherapy (CIRT) for patients with localized prostate cancer.

\textbf{Methods:} We enrolled 118 patients with localized prostate cancer who underwent treatment with spot-scanning CIRT at the Shanghai Proton and Heavy Ion Center (SPHIC) from January 2016 to December 2020. The dose was gradually increased from relative biological effectiveness (RBE)-weighted dose (D\textsubscript{RBE}) = 59.2–65.6 Gy in 16 fractions. The primary endpoint was the occurrence of acute and late toxicities, while the secondary endpoints were biochemical relapse-free survival (bRFS), distant metastasis-free survival (DMFS), prostate cancer-specific survival (PCSS), and overall survival (OS).

\textbf{Results:} The median follow-up time was 30.2 months (4.8–62.7 months). Acute grade 1 and 2 genitourinary (GU) toxicities were 15.3% and 18.6%, while acute grade 1 and 2 gastrointestinal (GI) toxicities were 2.5% and 0%, respectively. Late grade 1 and 2 GU toxicities were 4.2% and 1.7%, respectively. No late GI toxicity was observed. Moreover, there were no cases of severe acute or late toxicity (≥ grade 3). No significant association were observed between the factors and the acute GU toxicities, except for clinical target volume (CTV) (p = 0.031) on multivariate analysis. The 2-year bRFS, DMFS, PCSS, and OS were 100%, 100%, 100%, and 98.8%, respectively.

\textbf{Conclusion:} The 2-year outcomes were encouraging, providing additional and useful information on the feasibility and safety of spot-scanning CIRT for treating prostate cancer. Thus, we recommend long-term follow-up and prospective multicentered studies to reinforce the role of CIRT in the management of localized prostate cancer.

\textbf{Keywords:} prostate cancer, carbon ion radiotherapy, spot scanning, local effect model, toxicity
INTRODUCTION

Radiotherapy is a radical treatment option for localized prostate cancer. Randomized studies have demonstrated that dose-escalated radiotherapy improves cancer control (1, 2). However, increasing the dose leads to concerns about the toxicities in organs at risks (OARs), such as the rectum and bladder. Thus, if the dose to the prostate can be increased without increasing the dose to the OARs, the treatment outcome and quality of life of patients will be improved.

Carbon ion radiotherapy (CIRT) can minimize radiation dose to OARs while increasing the biologically effective dose delivery to the prostate (3, 4). According to the data from the particle Therapy Co-operative Group (https://www.ptcog.ch/) on June 2021, approximately 40,000 patients have been treated with CIRT in 12 carbon ion centers worldwide. The higher relative biological effectiveness (RBE) and greater cytocidal effect of CIRT on cancer cells make it more beneficial over conventional radiotherapy (5). Additionally, carbon ion beams produce the Bragg peak through the release of enormous energy at the end of their range (6), maximizing the destructive energy delivered to the tumor site while minimizing unwanted damage to the surrounding normal tissues (7, 8). These properties make CIRT theoretically efficient in improving tumor control and reducing radiation-related toxicity.

The first CIRT clinical trial for prostate cancer was started in Chiba, Japan in 1995 (8). This phase I/II dose escalation study established the efficacy and safety of CIRT. The following studies in Japan further confirmed the effectiveness of the CIRT with 16-fraction regimens (4, 9). However, different models were used to predict the RBE at different institutes. Two major RBE models have been applied clinically in CIRT: the Japanese model [the original mixed beam model and the modified micro-dosimetric kinetic model (MKM)] and Helmholtzzentrum für Schwerionenforschung GmbH (GSI) model [local effect model (LEM)] (10, 11). Comparative studies showed that the LEM predicts a 5%–15% higher RBE in the spread-out Bragg peak of a carbon ion beam, relative to the MKM (12). Similarly, findings from previous studies revealed that the RBE-weighed doses using MKM for targets and OARs should be converted to LEM doses using conversion curves for prostate cancer treated with CIRT (13). This hampers the exchange of experience between different CIRT facilities by the use of disparate RBE models. Thus, assessing the dose needed when using LEM model to achieve results similar to those reported by Japanese facilities will be of great value.

In 2014, the Shanghai Proton and Heavy Ion Center (SPHIC) started the first prostate cancer CIRT treatment in China. Till January 2021, more than 300 patients with prostate cancer have undergone particle therapy at our institute, including patients with localized prostate cancer, oligo-metastatic prostate cancer, prostate cancer with pelvic lymph node metastasis, and postoperative prostate cancer. To establish the optimal dose for CIRT in LEM model, dose-escalated clinical trials of CIRT for patients with localized prostate cancer began in January 2016 at our center (NCT02739659 and NCT04724577). The purpose of this study was to assess the 2-year toxicity, biochemical relapse-free survival (bRFS), distant metastasis-free survival (DMFS), prostate cancer-specific survival (PCSS), and overall survival (OS) of the 118 patients treated with CIRT in 16 fractions.

PATIENTS AND METHODS

Study Design and Patient Eligibility

We consecutively enrolled 118 patients with localized prostate cancer treated with 16 fractions CIRT at SPHIC between January 2016 and December 2020 through a retrospective design. Patients were included if they meet the following: (1) histological diagnosis of prostate adenocarcinoma, (2) cT1N0M0 to cT4N0M0 according to the 7th American Joint Committee on Cancer (AJCC) classification, (3) Karnofsky Performance Score ≥70, (4) without any previous surgery or radiotherapy for prostate cancer, and (5) the presence of written informed consent. We excluded patients who did not meet all of the aforementioned criteria.

The study was approved by the Institutional Review Board of SPHIC (Approval Number 180620EXP-02). Eligible patients gave their written informed consent for CIRT and for future anonymous use. All patients were treated by spot-scanning CIRT combined with or without hormone therapy in our institute. According to the National Comprehensive Cancer Network (NCCN) guidelines, patients with low-risk prostate cancer had no hormone therapy, while intermediate-risk patients received 4–6 months of hormone therapy, and high/very high-risk patients received hormone therapy for 2–3 years. The hormone therapy regimens were combined androgen blockade.

Carbon Ion Radiotherapy

Methods for preparing the bladder and rectum, immobilizing the patients, and setting clinical target volume (CTV) and planning target volume (PTV) have been described (14). Briefly, the CTV routinely included the prostate and seminal vesicle (seminal vesicle was excluded for low-risk patients), and pelvic lymph nodes were excluded from this study. Two opposite lateral beams were used for each fraction treatment. CIRT was given once a day, five fractions per week. The treatment position was adjusted before each fraction with orthogonal X-ray scans as image guide. Since May 2020, the daily in-room computed tomography (CT) was applied to guide the CIRT. The prescription was performed in terms of RBE-weighted dose (DRBE). RBE was calculated by the treatment planning system (Syngo), using the LEM model. The carbon ion was administered at a five-dose regimen of DRBE = 59.2/60.8/62.4/64/65.6 Gy in 16 fractions. OARs required for all the patients were the rectum and the bladder. The dose constraints of the rectum are as follow: Dmax (the max dose) <105% prescription dose (PD), V60 [volume receiving ≥60 Gy < 3 cc], V55 [volume receiving ≥55 Gy < 7 cc, and V50 [volume receiving ≥50 Gy] < 10 cc, which were referred from our previous dose conversion study (13, 14). The dose constraints on the bladder were Dmax <105% PD and V60...
[volume receiving ≥ 60 Gy] < 10%, V_{55} [volume receiving ≥ 55 Gy] < 15%, and V_{30} [volume receiving ≥ 30 Gy] < 30%.

**Follow-Up**
To closely monitor the patients, the patients’ follow-up was performed every week during treatment, and every 3 months until 3 years after CIRT, then sixth monthly until further notice. A rise in prostate-specific antigen (PSA) by at least 2 ng/ml above the nadir (the Phoenix definition) is considered as biochemical failure (15). For each patient, baseline parameters for genitourinary (GU) and gastrointestinal (GI) functions were assessed and acute, and late toxicities were scored by a physician using Common Terminology Criteria for Adverse Events v.4.03 and Radiation Therapy Oncology Group (RTOG) Classification (16). Acute toxicities are defined as side effects occurring within 3 months after the start of CIRT. Toxicities that occurred 3 months after the start of CIRT were considered late toxicities.

**Statistics**
The bRFS, DMFS, PCSS, and OS were evaluated using the Kaplan–Meier method. The bRFS, DMFS, PCSS, and OS were calculated from the start date of CIRT. The chi-square test was used to examine the difference in acute GU toxicities between the low-dose [D_{RBE} = 59.2–60.8 Gy] and high-dose [D_{RBE} = 62.4–65.6 Gy] groups. Logistic and Cox regression identified univariate and multivariate associations between toxicities and clinical/dosimetric characteristics. A two-sided p < 0.05 was considered statistically significant. All the analyses were performed using SPSS software (version 22.0; IBM Corp.).

**RESULTS**

**Patients Characteristics**
Table 1 shows the characteristics of the included patients. Their median age of the patients was 71 years old (range, 46–86 years). The median follow-up time was 30.2 months (4.8–62.7 months). According to the 7th AJCC classification, the number of patients with T1, T2, T3, and T4 was 5 (4.2%), 94 (79.7%), 17 (14.4%), and 2 (1.7%), respectively. The number of patients with Gleason score of 6, 7, and ≥8 was 32 (27.1%), 46 (39.0%), and 40 (33.9%), respectively. Before treatment, 45 patients had a PSA level <10 ng/ml, 42 had a PSA level ranging from 10 to 20 ng/ml, and 31 had a PSA level >20 ng/ml. According to the NCCN guideline, the number of patients at low-risk, intermediate-risk, and high/very-high risk patients was 9 (7.6%), 45 (38.1%), and 64 (54.2%), respectively. The number of patients irradiated with an RBE-weighted dose of 59.2, 60.8, 62.4, 64.0, and 65.6 Gy was 43 (36.4%), 10 (8.5%), 9 (7.6%), 25 (21.2%), and 31 (26.3%), respectively. All patients completed their spot-scanning CIRT.

**Acute Toxicities**
All patients were included in the analysis of acute and late toxicities. The acute toxicities are summarized in Table 2. The incidences of grades 1 and 2 acute GU toxicities were 15.3% and 18.6%, respectively. Moreover, eight (15.1%) and five (9.4%)...
patients developed grade 1 and 2 acute GU toxicities in the low-dose group, respectively, while 10 (15.4%) and 17 (26.2%) patients developed grade 1 and 2 acute GU toxicities in the high-dose group, respectively. The incidence of grade 2 acute GU toxicities of the high-dose group was higher than the low-dose group, although not significantly (p = 0.059). There were no significant differences in the frequency of acute GU toxicities, including hematuria, urinary frequency, urgency, retention, and urinary tract pain between the two groups (Table 2). CTV volume, bladder V60, V61, V62, and V63 were associated with ≥ grade 1 acute GU toxicities on univariate analysis, but only CTV volume was associated with ≥ grade 1 acute GU toxicities on multivariate analysis (Table 3).

Three (2.5%) patients developed grade 1 acute GI toxicities: one patient in the low-dose group and two patients in the high-dose group (p = 0.683). There were no significant differences in the frequency of acute GI toxicities manifested by symptoms, such as hematochezia and diarrhea. No patients demonstrated grade 2 or worse acute GI toxicity.

### Late Toxicities

Grade 1 late GU toxicities did not differ significantly between the low-dose group [2 (3.2%) of 62 patients] and the high-dose group [2 (3.6%) of 56 patients] (p = 0.158). Five patients developed grade 1 late GU toxicities; three patients presented with urinary frequency, and two patients presented with microscopic hematuria. Moreover, two patients developed grade 2 late GU toxicity (gross hematuria). No grade ≥ 3 late GU toxicity was observed across the groups. Furthermore, no patient suffered from late GI toxicity within the follow-up period (Table 4).

### Efficacy

The median follow-up time was 30.2 months (4.8–62.7 months). At the end of follow-up, five patients developed biochemical relapse, two patients received re-biopsy, but there was no evidence of tumor cells, and the PSA were stable without any treatment, such as hormone therapy. One patient received hormone therapy immediately after the diagnosis of PSA

**Table 2** | Acute toxicity between low-dose and high-dose groups.

| Total dose | D<sub>RBE</sub> = 59.2–60.8 Gy (n = 53) | P value |
|---|---|---|
| **GU** | | |
| Max toxicity | 0.585 | 0.059 |
| Urinary frequency | 0.931 | 0.081 |
| Urinary urgency | 0.877 | 0.622 |
| Urinary tract pain | 0.954 | 0.433 |
| Hematuria | 0.938 | 0.644 |
| Urinary retention | 0.923 | 0.258 |
| **GI** | | |
| Max toxicity | 0.964 | 0.683 |
| Hematochezia | 0.982 | 0.884 |
| Diarrhea | 0.962 | 0.364 |

**Table 3** | Univariate and multivariate clinical and DVH associations with acute GU toxicities (≥ grade 1).

| Variable | Univariate Cox regression | Multivariate Cox regression |
|---|---|---|
| Age | 1.001 (0.956–1.047) | 1.003 (0.952–1.056) |
| Diabetes mellitus | 1.531 (0.509–4.605) | 3.703 (0.881–15.564) |
| Internal use of anticoagulant | 0.559 (0.174–1.790) | 0.370 (0.077–1.775) |
| TURP | 2.171 (0.439–10.745) | 1.871 (0.275–12.730) |
| CTV volume | 1.016 (1.004–1.029) | 1.016 (1.001–1.031) |
| Bladder volume | 1.005 (0.997–1.013) | 1.002 (0.992–1.013) |
| Bladder Dmax | 1.105 (0.985–1.240) | 1.038 (0.919–1.173) |
| Bladder V30 | 1.022 (0.983–1.063) | 0.878 (0.463–1.664) |
| Bladder V40 | 1.030 (0.982–1.080) | 1.031 (0.319–3.336) |
| Bladder V50 | 1.045 (0.982–1.111) | 1.700 (0.489–5.912) |
| Bladder V55 | 1.059 (0.985–1.138) | 0.503 (0.167–1.513) |
| Bladder V60 | 1.092 (1.004–1.187) | 1.311 (0.443–3.881) |
| Bladder V61 | 1.106 (1.006–1.215) | 1.193 (0.147–9.673) |
| Bladder V62 | 1.129 (1.009–1.264) | 0.701 (0.135–3.647) |
| Bladder V63 | 1.178 (1.019–1.362) | 1.432 (0.642–3.192) |
| Bladder V65 | 1.227 (0.906–1.658) | 0.762 (0.442–1.313) |

**DVH**, dose–volume histograms; **GU**, genitourinary.
failure. Two patients who were classified as high- and very-high risk groups experienced bone metastases at 27.4 and 32.1 months after CIRT, respectively. A 72-year-old patient died at 20.6 months after CIRT due to cerebrovascular accident. No patient died of prostate cancer throughout the observation period. The 2-year bRFS, DMFS, PCSS, and OS was 100%, 100%, 100%, and 98.8%, respectively (Figure 1). The 2-year bRFS in low-, intermediate-, and high-/very-high risk groups was 100%, 100%, and 100%, respectively ($p = 0.782$) (Figure 2).

**DISCUSSION**

The improvement in biochemical relapse-free and OS of patients with prostate cancer was found to be dose dependent (17, 18). Several studies have shown the great potential of CIRT in the management of prostate cancer (3, 4, 8, 9), most from Japanese institutes. However, the biological model used in Europe and our center (LEM model) were different from that used in the Japanese institutes (MKM model) (19). Previous studies reveal that the RBE-weighted doses at our center are too conservative compared with those in Japanese institutes (13). The clinical study also found that the 5-year local control (71%) of skull base chordoma treated with CIRT at Centro Nazionale di Adroterapia Oncologica was inferior to the results reported by Japanese centers (76%–92%) using the same prescription dose, and they found that 92% of the local recurrences were attributable to suboptimal target dose in regions close to the brainstem or optic pathways (12, 20, 21). These studies indicated that the prescription dose from Japanese experiences for prostate cancer could not be replicated. Until now, the optimal dose for CIRT with LEM model in localized prostate cancer is not clear yet.

The first dose escalation clinical trial of CIRT for prostate cancer occurred in Japan. The 5-year bRFS of the 57.6 Gy in a 16-fraction regimen was 88.5% (9). In a multi-institutional study, which collected and re-analyzed data from prospective clinical trials conducted in three institutions in Japan, the 5-year bRFS in low-risk, intermediate-risk, and high-risk patients was 92%, 89%, and 92%, respectively (4). At first, 63/66 Gy in 23/24 fractions

| Dose regimens | Number of patients | Number of patients (%) with GU toxicity grade | p-value | Number of patients (%) with GI toxicity grade | p-value |
|---------------|--------------------|---------------------------------------------|---------|---------------------------------------------|---------|
|                |                    | 0 | 1 | 2 | ≥3 | | 0 | 1 | 2 | ≥3 |
| DRBE = 59.2–60.8Gy | 53 | 52 (98.1%) | 1 (1.9%) | 0 (0%) | 0 (0%) | 0.158 | 53 (100%) | 0 (0%) | 0 (0%) | 0 (0%) |
| DRBE = 62.4–65.6Gy | 65 | 65 (90.9%) | 2 (3.1%) | 0 (0%) | 0 (0%) | 65 (100%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Total | 118 | 111 (94.1%) | 5 (4.2%) | 2 (1.7%) | 0 (0%) | 118 (100%) | 0 (0%) | 0 (0%) | 0 (0%) |

GU, genitourinary; GI, gastrointestinal. NA, not applicable.

**FIGURE 1** | Outcome of 118 patients with prostate cancer treated with CIRT. (A) Biochemical relapse-free survival (bRFS); (B) distant metastasis free survival (DMFS); (C) prostate cancer-specific survival (PCSS); (D) overall survival (OS).
was applied to treat patients with prostate cancer in our institute. The dose regimens were well tolerated and without any ≥ grade 2 late GI and GU toxicities. In this study, we retrospectively evaluated the safety and feasibility of CIRT for patients with localized prostate cancer. By this, 118 patients treated by CIRT in our institute achieved satisfactory short-term biochemical control without developing serious adverse events.

In this study, 118 patients were treated with $D_{\text{RBE}} = 59.2 \text{ Gy}$ (n = 43), $60.8 \text{ Gy}$ (n = 10), $62.4 \text{ Gy}$ (n = 9), $64.0 \text{ Gy}$ (n = 25), and $65.6 \text{ Gy}$ (n = 31). Five patients developed biochemical relapse, all of which received 59.2Gy group. No patient in the ≥60.8 Gy groups developed biochemical relapse within the follow-up period. The comparative analysis for efficacy between low- and high-dose groups was not performed due to the relatively short follow-up time. The prescribed dose was $D_{\text{RBE}} = 57.6 \text{ Gy}$ in 16 fractions in the National Institute of Radiobiological Science, Japan. Our previous study showed that 3.60 Gy per fraction for 16 fractions in MKM could be converted to 4.21 Gy per fraction for 16 fractions in LEM (13). Hence, further evaluation of the efficacy of the fixed dose at 65.6 Gy in 16 fractions regimen in LEM model system is highly recommended.

In terms of acute toxicity, according to results from the RTOG 0126 clinical trial (22), in 751 patients treated with 79.2 Gy photon therapy, the incidence of grade 1–3 acute GU toxicity was 19%, 16%, and 1%, respectively, and the incidence of grade 1–and 3 acute GI toxicity was 7%, 7%, and <1%, respectively. Moreover, 91 patients were treated with $D_{\text{RBE}} = 66 \text{ Gy}$ in 20 fractions carbon ion or proton in the Ion Prostate Irradiation (IPI) study from Heidelberg Ion-Beam Therapy Center (HIT) (23), and the incidence of grade 1–3 acute GU toxicity was 34.1%, 17.6%, and 0%, respectively, and that of grade 1–3 acute GI toxicity was 60.4%, 7.7%, and 2.2%, respectively. In our study, patients in the high-dose group seem to experience higher rates of acute grade 2 GU toxicities than those in the low-dose group (26.2% vs. 9.4%). No ≥ grade 3 GU toxicity was observed in both groups. The incidence of acute GU toxicities in our study is consistent with that found in 79.2 Gy arms in the RTOG 0126 study but lower than that of the IPI study. The incidence of acute GI toxicity in our study is rare and significantly lower than that of the IPI study. A possible explanation for these differences may lie in that half of the patients received proton therapy in IPI, while daily in-room CT was applied to every patient with prostate cancer in our center since 2020. The association between the prognostic factors and the acute toxicities has been investigated in this study. We found that CTV volume was associated with acute GU toxicities. Previous studies also revealed that patients with large prostate volumes have a greater risk of irritative/obstructive symptoms (particularly dysuria) in the acute radiotherapy phase (24). This may be due to the fact that a greater bladder volume was irradiated and lower urinary bother score before CIRT for patient with large prostate was observed. Therefore, for patients with large prostate in our center, neoadjuvant hormone therapy is often recommended to reduce prostate volume.

Late toxicities tend to be more problematic than acute toxicities in radiotherapy for prostate cancer. The incidence rates of late grade 2 and 3 GU toxicities after radiotherapy were 11% and 3%, respectively, in the RTOG 0126 trial (79.2Gy arm) (22). According to the results of a multi-institutional study from the Japan Carbon Ion Radiation Oncology Study Group (J-CROS), which analyzed 2,157 patients treated with CIRT, the incidence rates of late grade 2 and 3 GU toxicities were 4.2% and 0%, respectively (4). In this study, the incidence rates of late grade 2 and 3 GI toxicities were 1.7% and 0%, respectively. The incidence rates of late grade 2 and 3 GI toxicities were 16% and 5%, respectively, in the RTOG 0126 trial (79.2 Gy arm). The incidence rates of late grade 2 and 3 GU toxicities were 0.5% and 0%, respectively, in the J-CROS trial, which were more favorable than photon therapy. In our study, no patient suffered from GI toxicity within the follow-up period, probably due to the short follow-up time. Ishikawa’s study showed that 81% of late toxicities occurred within 2 years after CIRT. The median follow-up time of patients in the low- and high-dose groups was 49 and 17 months, respectively (25). Therefore, toxicities were evaluated for a sufficient period in the low-dose group but not in the high-dose group.

This study had several limitations. First, the results were retrospectively analyzed from a single institution. A phase II study with a fixed dose of $D_{\text{RBE}} = 65.5 \text{ Gy}$ in 16 fractions is ongoing at our center. However, multicenter prospective studies are warranted to validate the safety and efficacy of carbon ion with the LEM model. Second, with 30.2 months follow-up, we could only assess acute and early late toxicities but not the long-term outcomes. Third, the sample size was small. Hence, the recruitment of more patients and a longer follow-up period are highly recommended.

**CONCLUSIONS**

In conclusion, the short-term results of spot-scanning carbon ion therapy for localized prostate cancer were encouraging. Our results provide additional and useful information on the feasibility and
**safety of CIRT with LEM model for patients with localized prostate cancer. Longer follow-up periods and multicenter prospective studies are warranted to confirm the biochemical control and survival benefit of this promising technique.**

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Shanghai Proton and Heavy Ion Center Institutional Review Board. The patients/participants provided their written informed consent to participate in this study.

**REFERENCES**

1. Dearnaley DP, Jovic G, Syndikus I, Vincent K, Cowan RA, Graham JD, et al. Escalated-Dose Versus Control-Dose Conformal Radiotherapy for Prostate Cancer: Long-Term Results From the MRC RT01 Randomised Controlled Trial. *Lancet Oncol* (2014) 15:464–73. doi: 10.1016/S1470-2045(14)70040-3

2. Heemsbergen WD, Al-Mamgani A, Slot A, Diedwart MF, Lebesque JV. Long-Term Results of the Dutch Randomized Prostate Cancer Trial: Impact of Dose-Escalation on Local, Biochemical, Clinical Failure, and Survival. *Radiother Oncol* (2014) 110:104–9. doi: 10.1016/j.radonc.2013.09.026

3. Takakusagi Y, Kato H, Kano K, Anno W, Tsuchida K, Mizoguchi N, et al. Preliminary Result of Carbon-Ion Radiotherapy Using the Spot Scanning Method for Prostate Cancer. *Radiother Oncol* (2020) 15(1):127. doi: 10.1186/13014-020-01575-7

4. Nomiyama T, Tsuji H, Kawamura H, Ohno T, Toyama S, Shiomyama Y, et al. A Multi-Institutional Analysis of Prospective Studies of Carbon Ion Radiotherapy for Prostate Cancer: A Report From the Japan Carbon Ion Radiation Oncology Study Group (J-CROS). *Radiother Oncol* (2016) 121(2):288–93. doi: 10.1016/j.radonc.2016.10.009

5. Tinganelli W, Durante M, Carbon Ion Radiobiology. *Cancers* (2020) 12(10):3022. doi: 10.3390/cancers12103022

6. Shiomyama Y, Tsuji H, Suefuji H, Sinoto M, Matsunobu A, Toyama S, et al. Particle Radiotherapy for Prostate Cancer. *Int J Urol* (2015) 22(1):33–9. doi: 10.1111/iju.12640

7. Schulz-Ertner D, Tsuji H. Particle Radiation Therapy Using Proton and Heavier Ion Beams. *J Clin Oncol* (2007) 25(8):953–64. doi: 10.1200/JCO.2006.09.7816

8. Akakura K, Tsuji H, Morita S, Tsuji H, Yagishita T, Isaka S, et al. Phase I/II Clinical Trials of Carbon Ion Therapy for Prostate Cancer. *Prostate* (2004) 58(3):252–8. doi: 10.1002/pro.10328

9. Ishikawa H, Tsuji H, Kamada T, Yanagi T, Mizoe J, Kanai T, et al. Carbon Ion Radiation Therapy for Prostate Cancer: Results of a Prospective Phase II Study. *Radiother Oncol* (2006) 81(1):57–64. doi: 10.1016/j.ijrobp.2012.01.072

10. Fossati P, Molinelli S, Matsufuji N, Ciocca M, Mirandola A, Mairani A, et al. Dose Prescription in Carbon Ion Radiotherapy: A Planning Study to Compare NIRS and LEM Approaches With a Clinically-Oriented Strategy. *Phys Med Biol* (2012) 57(22):7543–54. doi: 10.1088/0031-9155/57/22/7543

11. Fossati P, Matsufuji N, Kamada T, Karger CP. Radiobiological Issues in Prospective Carbon Ion Therapy Trials. *Med Phys* (2018) 45(11):e1096–110. doi: 10.1002/mp.12506

12. Koto M, Ikawa H, Kaneko T, Hagiwara Y, Hayashi K, Tsuji H. Long-Term Outcomes of Skull Base Chordoma Treated With High-Dose Carbon-Ion Radiotherapy. *Head Neck* (2020) 42(9):2607–13. doi: 10.1002/hed.26307

13. Wang WW, Huang ZJ, Sheng YS, Zhao JF, Shahnazi K, Zhang Q, et al. RBE-Weighted Dose Conversions for Carbon IonRadiotherapy Between Microdosimetric Kinetic Model and Local Effect Model for the Targets and Organs at Risk in Prostate Carcinoma. *Radiother Oncol* (2020) 144:30–6. doi: 10.1016/j.radonc.2019.10.005

14. Li YQ, Li P, Hsi W, Hong ZS, Fu S, Zhang Q. Normal Tissue Complication Probability (NTCP) Models of Acute Urinary Toxicity (AUT) Following Carbon Ion Radiotherapy (CIRT) for Prostate Cancer. *Radiother Oncol* (2021) 156:69–79. doi: 10.1016/j.radonc.2020.12.009

15. Rouk M, Hanks G, Thomas HCR, Schellhammer P, Shipley WW, Sokol GH, et al. Defining Biochemical Failure Following Radiotherapy With or Without Hormonal Therapy in Men With Clinically Localized Prostate Cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. *Int J Radiat Oncol Biol Phys* (2006) 65(4):965–74. doi: 10.1016/j.ijrobp.2006.04.029

16. Cox JD, Stez J, Pajak TF. Toxicity Criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). *Int J Radiat Oncol Biol Phys* (1995) 31(3):1541–6. doi: 10.1016/0360-3016(95)00966-C

17. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, et al. Long-Term Results of the M. D. Anderson Randomized Dose-Escalation Trial for Prostate Cancer. *Int J Radiat Oncol Biol Phys* (2008) 70(1):67–74. doi: 10.1016/j.ijrobp.2007.06.054

18. Kalbasi A, Li J, Berman A, Swisher-McClure S, Marc Smaldone M, Uzzo RG, et al. Dose-Escalated Irradiation and Overall Survival in Men With Nonmetastatic Prostate Cancer. *JAMA Oncol* (2015) 1(7):897–906. doi: 10.1001/jamaoncol.2015.2316

19. Molinelli S, Magro G, Mairani A, Matsufuji N, Kanematu N, Inanai T, et al. Dose Prescription in Carbon Ion Radiotherapy: How to Compare Two Different RBE-Weighted Dose Calculation Systems. *Radiother Oncol* (2016) 120(2):307–12. doi: 10.1016/j.radonc.2016.05.031

20. Iannalini A, D’Ippolito E, Riva G, Molinelli S, Gandini S, Viselner G, et al. Proton and Carbon Ions Radiotherapy in Skull Base Chordomas: A Prospective Study Based on a Dual Particle and a Patient-Customized Treatment Strategy. *Neuro Oncol* (2020) 22(9):1348–58. doi: 10.1093/neuo-oncology/noaa067

21. Tagaki M, Demizu Y, Nagano F, Terashima K, Fujii O, Jin D, et al. Treatment Outcomes of Proton or Carbon Ion Therapy for Skull Base Chordoma: A Retrospective Study. *Radiat Oncol* (2018) 13(1):232. doi: 10.1186/s13014-018-1173-0

**AUTHOR CONTRIBUTIONS**

PL, SF, and QZ conceived and designed the study. PL contributed data analysis and reagents. YL performed the physical data analysis. PL and ZH participated in patient treatment and follow-up. PL wrote the manuscript. SF and QZ reviewed the manuscript and contributed to the final version of the manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

Funding for this study was provided by the National Natural Science Foundation of China (81773225), Shanghai Municipal Health Commission (No. 201940121), and Pudong New Area Science and Technology Development Foundation (No. PKJ2020-Y52).
Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Li, Hong, Li, Fu and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.